Should I Buy DCGO? DCGO 2026 Analysis

Should You Buy DocGo Inc (DCGO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.810

1 Day change

-2.18%

52 Week Range

5.670

Analysis Updated At

2026/01/28

DCGO is not a good buy right now for a Beginner, long-term investor with $50k–$100k who wants to act immediately (not wait for a better setup). The stock is in a clear downtrend (bearish moving averages), fundamentals deteriorated sharply in 2025/Q3 (large revenue decline and widening losses), and there are no supportive proprietary trading signals today. While the latest news is modestly positive (telehealth staffing expansion), it is not enough to outweigh the weak trend and poor recent financial trajectory. Best action now: avoid/new money should not enter; if already holding, reduce/exit rather than add.

Technical Analysis

Trend/structure: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), signaling a sustained downtrend. Momentum: MACD histogram is slightly above zero (0.000399) but is positively contracting—this suggests any bounce is weakening rather than strengthening into a durable reversal. RSI(6) at ~42 is neutral-to-soft (not oversold), so there is no strong mean-reversion buy signal. Levels: Pivot 0.862 is overhead; price (~0.824–0.829 post-market) is below pivot, keeping bias bearish. Nearest support is S1 0.801 (then S2 0.764); a break below ~0.801 would likely invite another leg down. Resistance levels to reclaim for trend improvement are 0.862 (pivot) then 0.923 (R1). Short-horizon pattern stats provided are also weak/flat (next week expectation ~-0.07%, next month ~+0.16%), reinforcing lack of upside conviction. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment (with important caveat on liquidity): Put/call ratios are extremely call-skewed (OI PCR 0.08; volume PCR 0.33), which is typically bullish positioning. However, today’s total options volume is extremely low (4 contracts), meaning the ratios can be distorted and may not represent broad market conviction. Volatility: implied volatility is very high (IV30 ~121% vs historical vol ~104%) with IV percentile ~79, suggesting the options market is pricing large moves and/or elevated uncertainty; this is not ideal for a calm long-term entry signal. Net: headline bullish skew, but low participation and very high IV make this a speculative, not durable, sentiment read.

Technical Summary

Sell

Buy

Positive Catalysts

News-driven: SteadyMD (DocGo) plans to expand clinical staff up to 50% to meet telehealth demand, including GLP-1 weight-loss treatment programs—this supports a growth narrative and could help future revenue stability if execution is strong. Sentiment: options skew is call-heavy (though low-volume), indicating some traders are positioned for upside. No negative hedge fund or insider trend was observed in the provided data (both neutral), which removes one common source of near-term selling pressure.

Neutral/Negative Catalysts

Price action: sharp regular-session drop (-5.40%) and bearish moving-average stack indicate persistent selling pressure and a weak technical backdrop. Fundamentals: most recent quarter showed severe deterioration (large YoY revenue drop, widening loss, margin compression). Analyst framing: Canaccord kept a Hold and explicitly cited the need for meaningful adj-EBITDA loss improvement before expecting multiple expansion—this is a direct fundamental headwind for long-term re-rating. Options: extremely high implied volatility suggests uncertainty/risk is elevated rather than resolving.

Financial Performance

Latest quarter (2025/Q3): Revenue was 70,809,635, down -48.94% YoY (major contraction). Net income was -27,768,386 (down -605.07% YoY), indicating losses widened materially. EPS was -0.28 (down -660% YoY). Gross margin fell to 19.99%, down -39.39% YoY, showing meaningful profitability pressure. Overall trend: growth is negative and margins/losses are worsening, which is a poor setup for a long-term beginner-friendly buy right now.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend: Canaccord (2025-11-12) lowered the price target to $1.50 from $1.60 and maintained a Hold. Wall Street pro view (from the provided note): Pros—there may be operational value and the target implies upside from current levels. Cons—limited expectation for valuation/multiple expansion until there is clear improvement in adjusted EBITDA losses, implying the core issue is profitability/earnings trajectory rather than just revenue. Net: cautious/neutral stance with profitability improvement required before a more bullish view.

4 Analyst Rating

Wall Street analysts forecast DCGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCGO is 3.13 USD with a low forecast of 1.5 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.824

Low

1.5

Averages

3.13

High

Current: 0.824

Low

1.5

Averages

3.13

High

Canaccord

Hold

downgrade

AI Analysis

2025-11-12

Reason

Canaccord

Price Target

AI Analysis

2025-11-12

downgrade

Hold

Reason

Canaccord lowered the firm's price target on DocGo to $1.50 from $1.60 and keeps a Hold rating on the shares. The firm said while the price target does portend upside from current levels they believe that there is some value to be had for DocGo operations however, they do not see multiple expansion from a fundamental perspective until there is meaningful adj-EBITDA loss improvement.

Canaccord

Richard Close

Hold

maintain

2025-08-21

Reason

Canaccord

Richard Close

Price Target

2025-08-21

maintain

Hold

Reason

Canaccord analyst Richard Close raised the firm's price target on DocGo to $1.60 from $1.45 and keeps a Hold rating on the shares. The firm said DocGo showed some progress with its core business in 2Q as it works to replace the waning migrant services contract(s) that should be largely wound down entering 2H;however, there is much work to be done to rightsize the organization while also ramping up new business.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DCGO

Unlock Now

DCGO Should I Buy

DCGO Should I Buy

Should You Buy DocGo Inc (DCGO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch